NurExone Biologic Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor NurExone Biologic te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Pharmaceuticals winstgroei	53.6%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	14 Nov 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

We're Keeping An Eye On NurExone Biologic's (CVE:NRX) Cash Burn Rate

Jun 12

Winst- en omzetgroeiprognoses

TSXV:NRX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	N/A	N/A	N/A	N/A	1
12/31/2025	N/A	N/A	N/A	N/A	1
12/31/2024	N/A	N/A	N/A	N/A	1
6/30/2024	N/A	-4	-4	-4	N/A
3/31/2024	N/A	-4	-4	-4	N/A
12/31/2023	N/A	-4	-3	-3	N/A
9/30/2023	N/A	-4	-3	-3	N/A
6/30/2023	N/A	-4	-3	-3	N/A
3/31/2023	N/A	-7	-4	-4	N/A
12/31/2022	N/A	-8	-4	-4	N/A
9/30/2022	N/A	-8	-4	-4	N/A
6/30/2022	N/A	-7	-3	-3	N/A
3/31/2022	N/A	-4	-2	-2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van NRX boven de spaarquote ( 2.3% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van NRX naar verwachting sneller zal groeien dan de markt Canadian

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van NRX naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van NRX naar verwachting sneller zal groeien dan de markt Canadian.

Hoge groei-inkomsten: Er wordt verwacht dat NRX volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van NRX naar verwachting over 3 jaar hoog zal zijn

NurExone Biologic Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

New major risk - Shareholder dilution

NurExone Biologic Inc. announced that it expects to receive CAD 2 million in funding

New minor risk - Insider selling

NurExone Biologic Inc. Announces Significant Advancements in Their Manufacturing Process of Exosomes

NurExone Biologic Inc. Announces Further Expansion of ExoPTEN Patent Coverage

NurExone Biologic Inc. Announces Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s First Product ExoPTEN for Glaucoma

We're Keeping An Eye On NurExone Biologic's (CVE:NRX) Cash Burn Rate

New major risk - Financial position

New major risk - Shareholder dilution

NurExone Biologic Inc., Annual General Meeting, Jun 03, 2024

NurExone Biologic Inc. Expands Intellectual Property Portfolio

NurExone Biologic Inc. announced that it has received CAD 1.985758 million in funding

NurExone Biologic Inc. Appoints Eran Ovadya as Secretary

New major risk - Financial position

Nurexone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of Exopten Therapy for Acute Spinal Cord Injury Treatment

Nurexone Biologic Inc. Appoints Teodoro Forcht Dagi to Scientific Advisory Board and Advisory Committee

NurExone Biologic Inc. Secures Eureka Grant for Collaborative Partnership to Expand to Chronic Spinal Cord Injury Therapy

NurExone Biologic Inc. Moves Forward Towards Human Clinical Trials, Completes Pre-IND Meeting with FDA for Proprietary ExoPTEN Drug

Less than half of directors are independent

NurExone Biologic Inc. announced that it has received CAD 1.483501 million in funding

New minor risk - Shareholder dilution

NurExone Biologic Inc. Announces Board Changes

New minor risk - Shareholder dilution

NurExone Biologic Inc. announced that it expects to receive CAD 1.4 million in funding

NurExone Biologic Inc. Announces Advancements in Extracellular Vesicles Functionality with Enhanced Potency and Cellular Uptake for potentially better drug delivery

Nurexone Biologic Inc. Announces Board Changes

Nurexone Biologic Inc. Reports Positive Imaging Results from an Internal Preclinical Study of Its Investigational Drug ExoPTEN

NurExone Biologic Inc. Resignation of Eyal Flom from Board of Directors

Less than half of directors are independent

NurExone Announces Interim Positive Results of Internal Preclinical Study of Proprietary ExoPTEN Drug

United States Patent Office Allows Patent to NurExone Biologic Inc

Less than half of directors are independent

Nurexone Biologic Successfully Demonstrates Its Patent-Pending Platform Technology for Loading Exosomes with Therapeutic Molecules

Less than half of directors are independent

NurExone Biologic Inc. Announces Plan to Submit Pre- Investigational New Drug Meeting Request to U.S. Food and Drug Administration

NurExone Biologic Inc., Annual General Meeting, Dec 19, 2022

Less than half of directors are independent

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven